New insider activity at AbbVie ( (ABBV) ) has taken place on March 3, 2026.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
EVP, General Counsel and Secretary Perry C. Siatis has executed a notable stock sale involving AbbVie shares, unloading a total of 33,518 shares. The transaction amounts to a substantial $7,821,937 in AbbVie stock, highlighting a significant move by a key member of the company’s executive leadership team.
Recent Updates on ABBV stock
AbbVie shares reflected mixed sentiment over the last day as investors digested several clinical and capital-structure updates. Analysts highlighted that concerns about slowing immunology growth may be overdone, arguing AbbVie still has substantial room for indication expansion.
Recently completed post‑approval and observational studies for Skyrizi, upadacitinib, and the XEN45 glaucoma stent reinforced a strategy of de‑risking key franchises via real‑world and safety data, which can support confidence in long‑term revenues. A large bond issuance aimed at refinancing nearer‑term loans and extending maturities also fed into views that leverage remains a risk but is being actively managed, shaping more balanced price targets.
Spark’s Take on ABBV Stock
According to Spark, TipRanks’ AI Analyst, ABBV is a Neutral.
The score is primarily held back by balance-sheet risk (high leverage/negative equity) and an expensive P/E multiple despite solid cash generation. Offsetting these are constructive technicals and a notably positive earnings outlook with strong 2026 guidance driven by continued strength in key growth franchises.
To see Spark’s full report on ABBV stock, click here.
More about AbbVie
YTD Price Performance: 3.35%
Average Trading Volume: 6,577,637
Technical Sentiment Signal: Buy
Current Market Cap: $414.2B